Effect of Low Dose Intravenous Dexmedetomidine on Post Anesthesia Discharge After Day Case Breast Cancer Surgery
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Frequency of early discharge
研究概览
简要总结
A randomised control trial evaluating the effect of low dose dexmedetomidine infusion on post anesthesia discharge time in patients of day case breast cancer surgery compared with placebo infusion. The primary outcome was to compare the frequency of early discharge in each group.
详细描述
A prospective Randomised control trial evaluating the effect of low dose dexmedetomidine infusion on post anesthesia discharge time in patients of day case breast cancer surgery compared with placebo infusion. The primary outcome was to compare the frequency of early discharge in each group. Early discharge was defined as within two hours. The sample size was of 82 female patients with a specific inclusion and exclusion criteria. Randomisation was done through computer software and the trial was double blinded. SPSS version 22 will be used for data analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
盲法说明
Double blinded study, all participants, and the care provider providing anesthesia to the participants were blinded
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age 18-60 yrs, ASA 1 and 2, elective breast cancer surgery
排除标准
- •BMI greater than 35, CKD stage 3 or greater, known drug allergy to study drug, bradycardia, history of PONV, patients on antiepileptics
研究组 & 干预措施
Group A, receiving low dose dexmedetomidine infusion
Group A, receiving low dose dexmedetomidine infusion at 0.6mcg/kg/hour rate
干预措施: Dexmedetomidine infusion low dose (Drug)
Group B, receiving normal saline infusion as placebo
normal saline being used as placebo at rate 0.6mch/kg/hour rate
干预措施: Group B receiving normal saline (Drug)
结局指标
主要结局
Frequency of early discharge
时间窗: 120 minutes
post anesthesia discharge time within 2 hours
次要结局
未报告次要终点